{
    "id": 23670,
    "fullName": "MET exon14",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MET exon 14 indicates an unspecified mutation has occurred in exon 14 of the MET gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "exon14",
    "createDate": "06/24/2016",
    "updateDate": "03/12/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16451,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).",
            "molecularProfile": {
                "id": 24383,
                "profileName": "MET exon14"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 14521,
                    "pubMedId": 30165371,
                    "title": "PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165371"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16452,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).",
            "molecularProfile": {
                "id": 24383,
                "profileName": "MET exon14"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 14521,
                    "pubMedId": 30165371,
                    "title": "PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165371"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16453,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).",
            "molecularProfile": {
                "id": 24383,
                "profileName": "MET exon14"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 14521,
                    "pubMedId": 30165371,
                    "title": "PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165371"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16450,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).",
            "molecularProfile": {
                "id": 24383,
                "profileName": "MET exon14"
            },
            "therapy": {
                "id": 1356,
                "therapyName": "Durvalumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 14521,
                    "pubMedId": 30165371,
                    "title": "PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165371"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7064,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 100% (2/2) of non-small cell lung carcinoma patients harboring MET exon 14 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",
            "molecularProfile": {
                "id": 24383,
                "profileName": "MET exon14"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6064,
                    "pubMedId": null,
                    "title": "Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).",
                    "url": "http://meetinglibrary.asco.org/content/165406-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16454,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).",
            "molecularProfile": {
                "id": 24383,
                "profileName": "MET exon14"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 14521,
                    "pubMedId": 30165371,
                    "title": "PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165371"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14217,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tepotinib (MSC2156119J) treatment resulted in partial response in 60.0% (9/15) and stable disease in 20% (3/15) of patients with non-small cell lung cancer harboring MET exon 14 skipping mutations (J Clin Oncol 36, 2018 (suppl; abstr 9016); NCT02864992).",
            "molecularProfile": {
                "id": 24383,
                "profileName": "MET exon14"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11521,
                    "pubMedId": null,
                    "title": "Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.",
                    "url": "https://meetinglibrary.asco.org/record/160289/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19725,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in a response rate of 20.0% (2/9), with a median progression-free survival of 2.6 months, and a median overall survival of 3.8 months in patients with pre-treated non-small cell lung cancer harboring MET exon 14 mutations (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 24383,
                "profileName": "MET exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19759,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in a partial response in a patient with pre-treated non-small cell lung cancer harboring MET amplification and a mutation in exon 14 of MET (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 34502,
                "profileName": "MET exon14 MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24383,
            "profileName": "MET exon14",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34502,
            "profileName": "MET exon14 MET amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}